Hamed Emami1, Richard A P Takx2, Thomas Mayrhofer3, Sumbal Janjua2, Jakob Park2, Amit Pursnani2, Ahmed Tawakol2, Michael T Lu2, Maros Ferencik4, Udo Hoffmann5. 1. Cardiac MR PET CT Program, Division of Cardiovascular Imaging, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts; Department of Internal Medicine, Yale-New Haven Hospital, Yale Medical School, New Haven, Connecticut. 2. Cardiac MR PET CT Program, Division of Cardiovascular Imaging, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts. 3. Cardiac MR PET CT Program, Division of Cardiovascular Imaging, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts; School of Business Studies, Stralsund University of Applied Sciences, Stralsund, Germany. 4. Cardiac MR PET CT Program, Division of Cardiovascular Imaging, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts; Knight Cardiovascular Institute, Oregon Health and Science University, Portland, Oregon. 5. Cardiac MR PET CT Program, Division of Cardiovascular Imaging, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts. Electronic address: uhoffmann@partners.org.
Abstract
OBJECTIVES: This study sought to determine prognostic value of nonobstructive coronary artery disease (CAD) for atherosclerotic cardiovascular disease (ASCVD) events and to determine whether incorporation of this information into the pooled cohort equation reclassifies recommendations for statin therapy as defined by the 2013 guidelines for cholesterol management of the American College of Cardiology and American Heart Association (ACC/AHA). BACKGROUND: Detection of nonobstructive CAD by coronary computed tomography angiography may improve risk stratification and permit individualized and more appropriate allocation of statin therapy. METHODS: This study determined the pooled hazard ratio of nonobstructive CAD for ASCVD events from published studies and incorporated this information into the ACC/AHA pooled cohort equation. The study calculated revised sex- and ethnicity-based 10-year ASCVD risk and determined boundaries corresponding to the original 7.5% risk for ASCVD events. It also assessed reclassification for statin eligibility by incorporating the results from meta-analysis to individual patients from a separate cohort. RESULTS: This study included 2 studies (2,295 subjects; 66% male; prevalence of nonobstructive CAD, 47%; median follow-up, 49 months; 67 ASCVD events). The hazard ratio of nonobstructive CAD for ASCVD events was 3.2 (95% confidence interval: 1.5 to 6.7). Incorporation of this information into the pooled cohort equation resulted in reclassification toward statin eligibility in individuals with nonobstructive CAD, with an original ASCVD score of 3.0% and 5.9% or higher in African-American women and men and a score of 4.4% and 4.6% or higher in Caucasian women and men, respectively. The absence of nonobstructive CAD resulted in reclassification toward statin ineligibility if the original ASCVD score was as 10.0% and 17.9% or lower in African-American women and men and 13.7% and 14.3% or lower in Caucasian women and men, respectively. Reclassification is observed in 14% of patients. CONCLUSIONS: Detection of nonobstructive CAD by coronary computed tomography angiography improves risk stratification and permits individualized and more appropriate allocation of statin therapy across sex and ethnicity groups.
OBJECTIVES: This study sought to determine prognostic value of nonobstructive coronary artery disease (CAD) for atherosclerotic cardiovascular disease (ASCVD) events and to determine whether incorporation of this information into the pooled cohort equation reclassifies recommendations for statin therapy as defined by the 2013 guidelines for cholesterol management of the American College of Cardiology and American Heart Association (ACC/AHA). BACKGROUND: Detection of nonobstructive CAD by coronary computed tomography angiography may improve risk stratification and permit individualized and more appropriate allocation of statin therapy. METHODS: This study determined the pooled hazard ratio of nonobstructive CAD for ASCVD events from published studies and incorporated this information into the ACC/AHA pooled cohort equation. The study calculated revised sex- and ethnicity-based 10-year ASCVD risk and determined boundaries corresponding to the original 7.5% risk for ASCVD events. It also assessed reclassification for statin eligibility by incorporating the results from meta-analysis to individual patients from a separate cohort. RESULTS: This study included 2 studies (2,295 subjects; 66% male; prevalence of nonobstructive CAD, 47%; median follow-up, 49 months; 67 ASCVD events). The hazard ratio of nonobstructive CAD for ASCVD events was 3.2 (95% confidence interval: 1.5 to 6.7). Incorporation of this information into the pooled cohort equation resulted in reclassification toward statin eligibility in individuals with nonobstructive CAD, with an original ASCVD score of 3.0% and 5.9% or higher in African-American women and men and a score of 4.4% and 4.6% or higher in Caucasian women and men, respectively. The absence of nonobstructive CAD resulted in reclassification toward statin ineligibility if the original ASCVD score was as 10.0% and 17.9% or lower in African-American women and men and 13.7% and 14.3% or lower in Caucasian women and men, respectively. Reclassification is observed in 14% of patients. CONCLUSIONS: Detection of nonobstructive CAD by coronary computed tomography angiography improves risk stratification and permits individualized and more appropriate allocation of statin therapy across sex and ethnicity groups.
Authors: Jarett D Berry; Alan Dyer; Xuan Cai; Daniel B Garside; Hongyan Ning; Avis Thomas; Philip Greenland; Linda Van Horn; Russell P Tracy; Donald M Lloyd-Jones Journal: N Engl J Med Date: 2012-01-26 Impact factor: 91.245
Authors: Kristian A Ovrehus; Hans E Bøtker; Jesper M Jensen; Henrik Munkholm; Søren P Johnsen; Bjarne L Nørgaard Journal: Am J Cardiol Date: 2011-03-21 Impact factor: 2.778
Authors: Neil J Stone; Jennifer G Robinson; Alice H Lichtenstein; C Noel Bairey Merz; Conrad B Blum; Robert H Eckel; Anne C Goldberg; David Gordon; Daniel Levy; Donald M Lloyd-Jones; Patrick McBride; J Sanford Schwartz; Susan T Shero; Sidney C Smith; Karol Watson; Peter W F Wilson Journal: J Am Coll Cardiol Date: 2013-11-12 Impact factor: 24.094
Authors: Tamar S Polonsky; Robyn L McClelland; Neal W Jorgensen; Diane E Bild; Gregory L Burke; Alan D Guerci; Philip Greenland Journal: JAMA Date: 2010-04-28 Impact factor: 56.272
Authors: D F Stroup; J A Berlin; S C Morton; I Olkin; G D Williamson; D Rennie; D Moher; B J Becker; T A Sipe; S B Thacker Journal: JAMA Date: 2000-04-19 Impact factor: 56.272
Authors: Iksung Cho; Hyuk-Jae Chang; Bríain Ó Hartaigh; Sanghoon Shin; Ji Min Sung; Fay Y Lin; Stephan Achenbach; Ran Heo; Daniel S Berman; Matthew J Budoff; Tracy Q Callister; Mouaz H Al-Mallah; Filippo Cademartiri; Kavitha Chinnaiyan; Benjamin J W Chow; Allison M Dunning; Augustin DeLago; Todd C Villines; Martin Hadamitzky; Joerg Hausleiter; Jonathon Leipsic; Leslee J Shaw; Philipp A Kaufmann; Ricardo C Cury; Gudrun Feuchtner; Yong-Jin Kim; Erica Maffei; Gilbert Raff; Gianluca Pontone; Daniele Andreini; James K Min Journal: Eur Heart J Date: 2014-09-08 Impact factor: 29.983
Authors: Khurram Nasir; Marcio S Bittencourt; Michael J Blaha; Ron Blankstein; Arthur S Agatson; Juan J Rivera; Michael D Miedema; Michael D Miemdema; Christopher T Sibley; Leslee J Shaw; Roger S Blumenthal; Matthew J Budoff; Harlan M Krumholz Journal: J Am Coll Cardiol Date: 2015-10-13 Impact factor: 24.094
Authors: Martin Hadamitzky; Stephan Achenbach; Mouaz Al-Mallah; Daniel Berman; Matthew Budoff; Filippo Cademartiri; Tracy Callister; Hyuk-Jae Chang; Victor Cheng; Kavitha Chinnaiyan; Benjamin J W Chow; Ricardo Cury; Augustin Delago; Allison Dunning; Gudrun Feuchtner; Millie Gomez; Philipp Kaufmann; Yong-Jin Kim; Jonathon Leipsic; Fay Y Lin; Erica Maffei; James K Min; Gil Raff; Leslee J Shaw; Todd C Villines; Jörg Hausleiter Journal: J Am Coll Cardiol Date: 2013-05-30 Impact factor: 24.094
Authors: Michael J Pencina; Ann Marie Navar-Boggan; Ralph B D'Agostino; Ken Williams; Benjamin Neely; Allan D Sniderman; Eric D Peterson Journal: N Engl J Med Date: 2014-03-19 Impact factor: 91.245
Authors: Fabian Plank; Guy Friedrich; Wolfgang Dichtl; Andrea Klauser; Werner Jaschke; Wolfgang-Michael Franz; Gudrun Feuchtner Journal: Open Heart Date: 2014-08-12
Authors: Pavithra S Jayadeva; Stephen Stowers; E W Tang; Joao Vitola; Rodrigo Cerci; Jessica Yao; James Westcott; Barry Elison; Nathan Better Journal: J Nucl Cardiol Date: 2022-09-12 Impact factor: 3.872
Authors: Andreas A Kammerlander; Thomas Mayrhofer; Maros Ferencik; Neha J Pagidipati; Julia Karady; Geoffrey S Ginsburg; Michael T Lu; Daniel O Bittner; Stefan B Puchner; Nathan A Bihlmeyer; Nandini M Meyersohn; Hamed Emami; Svati H Shah; Pamela S Douglas; Udo Hoffmann Journal: Diabetes Care Date: 2021-02-08 Impact factor: 19.112
Authors: Borek Foldyna; Roman Zeleznik; Parastou Eslami; Thomas Mayrhofer; Jan-Erik Scholtz; Maros Ferencik; Daniel O Bittner; Nandini M Meyersohn; Stefan B Puchner; Hamed Emami; Patricia A Pellikka; Hugo J W L Aerts; Pamela S Douglas; Michael T Lu; Udo Hoffmann Journal: Eur Radiol Date: 2021-01-26 Impact factor: 7.034